Status:
COMPLETED
High Frequency and Intensive Prevention Program
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Parkinson Schweiz
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-86 years
Phase:
NA
Brief Summary
The treatment of PD has made considerable advances in recent years with respect to drug therapies, as well as many new physiotherapy and drug-based methods, and there have also been great improvements...
Detailed Description
Cognitive decline is an important and common complication in Parkinson's Disease (PD); approximately 27% of non-demented PD patients have Mild Cognitive Impairment (MCI) (Litvan et al. 2012, Chaudhuri...
Eligibility Criteria
Inclusion
- Patients with idiopathic Parkinson syndrome according to United Kingdom Parkinson's Disease Brain Bank Criteria
- mental competence to provide informed consent
- able to understand German sufficiently
Exclusion
- Severe dementia (DMS-IV, mini mental Status (MMS) \<24, moca test (MoCa) \<21)
- young onset Parkinson's disease (\<18y)
- other neurological or psychiatric diseases of the brain not related to PD
- secondary parkinsonism
- physical impairment hindering the adequate execution of the training
- insufficient knowledge of German
- pregnancy
- Deep Brain Stimulation (DBS) is no exclusion criterion.
Key Trial Info
Start Date :
July 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04103255
Start Date
July 10 2020
End Date
February 1 2022
Last Update
January 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Switzerland, 4031